Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma
Prior to the advent of immuno-oncology agents for HER2+ advanced gastric/GEJ adenocarcinoma (2011-2019), the economic burden was substantial throughout patients' treatment journey, whereas OS ranged from 12.0 to 15.3 months. During this period, trastuzumab with chemo-monotherapy backbones was often used in older patients. These real-world benchmarks offer valuable context for evaluating the impact of newer therapies in this population.
Authors
- Zhou Zheng-yi
- L. Wang
- Adriana Valderrama (ORCID: https://orcid.org/0000-0003-4480-3879)
- Sofya Pintova (ORCID: https://orcid.org/0000-0001-7750-204X)
- Matthew Mattera (ORCID: https://orcid.org/0009-0001-4418-7263)
- Travis Wang (ORCID: https://orcid.org/0000-0002-1175-1884)
- Kanu Priya Sharan
- Aolin Wang
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Gwynedd Mercy University (US)
- Analysis Group (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-12-24
- DOI
- https://doi.org/10.18553/jmcp.2026.32.1.53
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00